BridgeBio Pharma, Inc.

Pharmaceutical Preparations

BBIOStrained3 of 9 basics passed

$65.35

+0.48%

Market cap $12.8B

$65.35

+0.48%

Market cap $12.8B

BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy.

It is a $12.8B healthcare company. Revenue grew 202.4% over the last year, it currently loses money, and it carries $1.26B of net debt.

Website: bridgebio.com
Location: Palo Alto, CA
Employees: 839
Sector: Healthcare

Share price · 3 years

$26.54 → $65.35+146.2%

price only — dividends excluded

Key facts · TTM

Revenue: total sales; $713M
Loss: spends more than it earns; -$692M
Free cash flow: cash left after running the business; -$435M
Net debt: debt minus cash on hand; $1.26B
Shares: up 30% since 2022 — dilution; 191.5M
Volatility: beta vs the market — under 1 swings less; 0.95

Revenue, last 7 years

52-week range

Low $53.24$65.35High $90.17

Today's price is 33% of the way from the year's low to its high.

Valuation vs own history

P/S

17.9×

88%

Share of the last ~5 years that was pricier than today (unusually cheap vs its own history). Based on the daily valuation record.

Insider activity · 90 days

-$4.42Mnet selling

Purchases$0

Sales$4.42M

Insiders trading, last 14d0 buy · 0 sell

Standing in Healthcare

Size$12.8Btop 69%
Revenue growth+86%top 3%
Net margin-97%top 93%
Return on equity-207%top 98%

Ranked against 98 Healthcare companies with a full CV — for P/E, lower ranks higher.

Skills

Six independent scores, 0–100, built from reported numbers and valuation history. Click a row to see how it was scored.

Valuation, Growth, Profitability, Health, Quality and Moat lag behind.

Valuation25

P/E vs own historyn/a · 10/25
FCF yield-3.4% · 0/25
P/S17.9x · 5/25
EV/EBITDAn/a · 10/25

Growth25

Revenue CAGR63.8% · 25/25
Net income CAGRn/a · 0/25
EPS CAGR ~5Yn/a · 0/25
Fwd implied growthn/a · 0/25

Profitability0

ROICn/a · 0/25
ROE-206.7% · 0/25
Net margin-97.0% · 0/25
Operating margin-69.8% · 0/25

Health15

Altman Z-2.72 · 3/25
Current ratio1.23 · 12/25
Interest coverage-2.2x · 0/25
Net cash / debtD/A 135% · 0/25

Quality30

Piotroski F2/9 · 5/25
Beneish M-4.29 · 25/25
FCF conversionn/a · 0/25
Margin stabilityσ 7214.4% · 0/25

Moat25

ROIC >12% yearsn/a · 0/25
Median gross margin95.8% · 25/25
FCF-positive years0/7 yrs · 0/25
Worst-year net marginworst -6913.9% · 0/25

How the scores work →

Experience

The company's career so far — founding, the IPO, landmark products and acquisitions, plus revenue milestones and insider buying.

FY2024Financial
Became debt-free
cash now exceeds total debt

Achievements

Verifiable track record, straight from the reported numbers.

$10 000 invested in 2021 would be worth ~$13 086 today — price return only

$502.1M revenue in FY2025

Revenue up 202.4% year over year

839 employees

Strengths & watch-outs

What a bull and a bear would each point to. Both lists come from the reported numbers, not opinions.

Strengths

High gross margin (94.4%)
Revenue growing 202.4% year over year

Watch-outs

Not profitable — 97.0% net margin
Negative free cash flow (-$435.4M)
Altman Z-Score -2.72 — elevated financial-distress risk
Thin interest coverage (-2.2×)
Loss-making in 7 of the recent years

Qualifications

The basics a company should meet before you research it further. Each check uses the reported numbers.

3 of 9 checks passed

Revenue growing — the company sells more than a year ago+202.4% YoY
Profitable — makes more than it spends-$692M TTM
Profit growing — earnings are higher than last year-35.3% YoY
Generates cash — cash left after running and investing-$435M TTM
Debt under control — could handle its obligationscurrent ratio 1.23
Established company — not a micro-cap — lower blow-up risk$12.8B market cap
Not printing shares — share count not ballooning — you keep your slice+29.9% shares over ~5y
Proven track record — years of profitability behind it0/7 profitable years
Financially stable — balance sheet not near distressAltman Z -2.7 — distress
Pays a dividend — returns cash to shareholdersno data
Valuation not extreme — price not wildly above earningsno data

Peer comparisonBridgeBio Pharma, Inc. vs 6 largest healthcare peers — cap, P/E, growth and margin side by sideOpen ▾

Company	Market cap	P/E	Revenue growth	Net margin	Profile
BBIO this company	$12.8B	—	+202.4%	-97.0%	Strained
LLY Eli Lilly & Co.	$1.0T	41.6	+49.6%	33.5%	Solid
JNJ Johnson & Johnson	$630.9B	29.9	+8.1%	21.5%	Mixed
ABBV Abbvie Inc.	$488.5B	77.4	+10.4%	9.8%	Mixed
MRK Merck & Co., Inc.	$361.0B	113.2	+4.6%	4.8%	Mixed
UNH UNITEDHEALTH GROUP INCORPORATED (Delaware)	$340.7B	24.1	+6.5%	3.1%	Mixed
NVS Novartis AG	$273.2B	20.3	+9.6%	24.7%	Solid

Head-to-head: BBIO vs LLY · BBIO vs JNJ · BBIO vs ABBV

References

What covering analysts publish about the company — information only, not a recommendation.

Strong buy 6Buy 20Hold 3

Appendix · Financial records

The full statements behind this CV, FY2019–FY2025. For readers who want to check the numbers.

Profit & lossRevenue $713M · net income -$692M (TTM)Open ▾

Profit & loss

Revenue and profit over the company's career — the income statement, visualised.

How FY2025 revenue flows to profit

RevenueNet income

Revenue (TTM)

$713M

YoY 202.4%

Net income (TTM)

-$692M

Margin -97.0%

Gross margin

94.4%

Operating margin

-69.8%

Income statement — full detail

Figures in USD billions · EPS in USD

	2020	2021	2022	2023	2024	2025
Revenue	0.0	0.1	0.1	0.0	0.2	0.5
Gross profit	—	0.1	-0.5	0.0	0.2	0.5
Operating income (EBIT)	-0.5	-0.6	-0.5	-0.6	-0.6	-0.5
Net income	-0.4	-0.6	-0.5	-0.6	-0.5	-0.7
EPS (diluted)	—	—	-3.26	-3.67	-2.88	-3.78

Cash flowFree cash flow -$435M · operating cash flow -$434M (TTM)Open ▾

Cash flow statement

Cash generated by the business and what is left after investment — year by year.

Operating cash flowFree cash flow

Free cash flow (TTM)

-$435M

Margin -61.1%

Operating cash flow (TTM)

-$434M

FCF margin

-61.1%

Cash flow statement — full detail

Figures in USD billions

	2020	2021	2022	2023	2024	2025
Operating cash flow	-0.4	-0.5	-0.4	-0.5	-0.5	-0.4
Capital expenditure	-0.0	-0.0	-0.0	-0.0	-0.0	-0.0
Free cash flow	-0.4	-0.5	-0.4	-0.5	-0.5	-0.4
FCF margin	-4936.7%	-733.2%	-546.5%	-5686.6%	-235.1%	-89.0%

Balance sheetAssets $936M · net debt $1.26B (FY2025)Open ▾

Balance sheet

How the balance sheet is built — what it owns versus how it is financed.

How $936M of assets is financed

325%

Liabilities $3.01B — borrowed moneyEquity -$2.09B — owners' stake

Cash vs debt

Total debt $1.85B − cash $587M = net debt $1.26B

Cash on hand covers 32% of debt.

Altman Z-Score

-2.72

Distress zone

Interest coverage

-2.2x

EBIT ÷ interest expense

ROE

-206.7%

Profit per $1 of equity

Balance sheet — full detail

Figures in USD billions

	2020	2021	2022	2023	2024	2025
Cash & equivalents	0.6	0.8	0.4	0.4	0.7	0.6
Total assets	0.7	1.0	0.6	0.5	0.9	0.9
Total liabilities	0.6	1.9	1.9	1.9	2.4	3.0
Total debt	0.1	0.4	0.4	1.7	0.4	1.9
Equity	0.1	-0.9	-1.3	-1.3	-1.5	-2.1
Net debt	-0.5	-0.4	0.0	1.3	-0.2	1.3

Want the live picture — intraday moves, valuation history and full analysis?

Deeper analysis of BBIO on PreMarketPrice

Figures are derived from company filings (quarterly values normalised from as-filed year-to-date data where applicable) and may be delayed, restated or incomplete. This page is information, not investment advice. Latest price $65.35 · market cap $12.8B.